A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT07136077 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Minimal Residual Disease
Adjuvant Chemotherapy
Colorectal Cancer
Fruquintinib
Tislelizumab
ctDNA

Interventions

DRUG: Tislelizumab
DRUG: Fruquintinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]